New Orleans, LA (PRWEB) December 11, 2013
WavePharma, LLC, developer of an innovative, extended release and transdermal delivery technology, WP-ChitosanTM, announced today the launch of its modified chitosan for use in the multi-billion dollar cosmetics and pharmaceutical industries. WavePharma is actively seeking development partners to integrate these materials into their personal and skin care formulations.
Native, unmodified chitosan comes from chitin, a natural substance that has been a mainstay in many skin and hair care products for years because of its moisturizing, protective, elastic, antibacterial/antifungal, and biodegradable properties. WavePharma’s modified chitosan retains these properties, plus unlocks premium benefits such as adjustable water retention (hydration), custom bonding of molecules or active ingredients, superior adhesion compared with market leading products, the ability to control the thickness of gels and creams, as well as the ability to control the release of active ingredients and therapeutic agents.
“Our WP-chitosan is more than just a technical advancement, a new feature, or even a new product; it’s a new material. It is chitosan-based, but it’s chemically and physically different than non-modified chitosan and has a number of novel, useful properties to advance skin care, transdermal delivery of active agents, and hair care,” said Jack Foster, CEO of WavePharma.
Much of the WP-chitosan proof-of-concept work to date was sponsored by a market leader in eye medications and focused on controlled release of drugs in the eye. WP-chitosan modified pharmaceutical agents demonstrated long-term retention on the cornea and extended agent delivery profiles and bioavailability. WavePharma is evaluating chitosan-enhanced products for improved retention of actives for the
Copyright©2012 Vocus, Inc.
All rights reserved